Lunit Presents 11 Research Abstracts at ASCO

[Asia Economy Reporter Chunhee Lee] Medical artificial intelligence (AI) company Lunit announced on the 28th that 11 solo and joint research papers (7 posters, 4 online) have been accepted at the 2022 American Society of Clinical Oncology (ASCO 2022), to be held in Chicago, USA, this June.

Lunit has been presenting research abstracts at ASCO annually since 2019. This year, a total of 11 papers will be presented, marking the largest scale of research results.

Using the AI biomarker ‘Lunit Scope IO,’ Lunit conducted research by classifying cancer patients into three immune phenotypes according to their immunological characteristics. As a result, Lunit will present research at this ASCO demonstrating the significance of Lunit Scope IO as a model predicting the treatment outcomes of immune checkpoint inhibitors across more than 16 different cancer types.

Additionally, research evaluating the clinical utility of the AI-based pathology analysis solution ‘Lunit Scope PD-L1’ when used by actual pathologists during the interpretation process will also be presented.

Along with this, Lunit will introduce a new AI imaging analysis solution that predicts the risk of future breast cancer development in patients currently without detected cancer through mammography screening, showing more accurate predictions than existing breast cancer risk models.

Furthermore, Lunit will present four online research abstracts, including a collaborative study with other institutions that developed Lunit Scope HER2 to reduce inter-observer variability, and research analyzing that Lunit Scope IO can also analyze rare cancers such as neuroendocrine tumors, revealing significant differences in the distribution of tumor-infiltrating lymphocytes (TILs) according to pathological grade.

Seobeomseok, CEO of Lunit, said, "We have once again confirmed the potential application of Lunit Scope IO in treating patients with a wider variety of cancer types," adding, "We will continue diverse research activities so that patients can experience a higher level of medical service through AI."